Cure My Disease

Don't miss your cure!

 Log in / Sign up

New epilepsy drug aims to cut brief staring spells in half

NCT ID NCT06769659

Recruiting now Symptom relief Sponsor: NeuroPro Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an experimental drug called NPT 2042 can reduce the number and length of absence seizures (brief staring spells) in people aged 16-75 with genetic generalized epilepsy. Each participant will receive both the drug and a placebo in random order, with a two-week break in between. The trial is small (12 people) and is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY, ABSENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood absence epilepsy Epilepsy, Absence Epilepsy, Generalized generalized epilepsy genetic generalized epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY, ABSENCE EPILEPSY, GENERALIZED

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Trials, Inc. (CTI)

    RECRUITING

    Little Rock, Arkansas, 77205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.